A 22-year old breast cancer patient has issued a heartfelt plea to young women, urging them to carry out vital checks. Holly Ives, from Chellaston, has been fighting to raise awareness for the disease ...

Florida State football fans celebrated the end of a four-game losing streak by waving their shirts in the stands. The celebration involved roughly 100 shirtless fans in the student section during a 42 ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A dip in Canadian tourism, new ...

After a slow start to the 2025 NFL season, Minnesota Vikings wide receiver Justin Jefferson has finally hit his stride. Moreover, the LSU product has exploded in his last two games, posting over 100 ...

A Montgomery County high school recently returned its senior class T-shirts after administrators said the design celebrated the class of 2026 in a way that “evokes the N-word,” according to a recent ...

School leaders are apologizing after what looks to be a racial slur was printed on t-shirts. Trump wants to ‘end’ largest US infrastructure project, a tunnel between NY and NJ Scientists Discovered A ...

A group of Grand Prairie residents say they're frustrated and powerless to stop a proposed high-density housing development in their neighborhood — and they blame a new state law for taking away their ...

What’s up, y’all. Welcome back to The Morning Win. Who’s ready for the Icy Hot Bowl? That's what they're calling the geriatric matchup between Aaron Rodgers and Joe Flacco tonight. And ready or not, ...

In recent hours, Donald Trump has experienced some of the happiest moments of his political life. He seemed positively exultant at the peace agreement signing ceremony. Everything was full of reasons ...

A threatened tariff that is never implemented does not hurt the economy as much as a threatened tariff that is actually implemented. That simple point seems to have eluded Matthew Lynn, a financial ...

Tvardi Therapeutics shares were 30% lower, at $7.19, in premarket trading after the company said its phase 2 study for TTI-101 didn't meet its goals. TTI-101 is a small molecule therapy targeting ...